BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
Abbott stock fell more than 7% in premarket trading after the company missed on Q4 revenue and gave a weaker Q1 2026 outlook, even with earnings at $1.50 per share.
Exact Sciences surged more than 17% premarket after Abbott announced a $23 billion buyout, adding Cologuard and Oncotype DX to its diagnostics lineup.
Abbott Laboratories reported a strong start to 2025 with significant growth in sales and EPS, exceeding market expectations.
Abbott Laboratories reported a strong third-quarter performance in 2024.
Abbott Laboratories (NYSE: ABT) reported sales of $10.4 billion in the second quarter of 2024, reflecting a 4.0% increase from the same period last year.
Abbott has reported a strong start to the year with sales reaching $10.0 billion in Q1, driven by a 10.8 percent increase in organic sales growth.
Abbott Laboratories announces Q4 results with $10.24 billion in revenue and an EPS of $1.19.